Research Articles

6 High Yield Pharmaceutical Companies: Do They Justify the Risk?

Julie C - Wednesday, January 12, 2011

Introduction

Today Investors are keenly focused on income while simultaneously very risk averse. This current behavior brings with it a level of frustration. The appetite for yield is high precisely at a time when yields on the traditionally safest investments like bonds and CDs, etc. are at historic lows. On the other hand, dividend yields on many blue-chip stocks are close to double what investors would normally find with this asset class.

In many cases, these abnormally high yields are purely a function of historically low valuations. Ironically, the only logical reason that we can identify as to why valuations of blue-chip stocks are so low is fear (risk aversion).

The Many Faces of Risk

In truth, the concept of risk is a multifaceted subject. Yet investors and writers often throw the word around as if it had a single or universal meaning. In reality, there are many faces to risk and prudent investors need to consider and evaluate them all before making investment decisions. Of course the most obvious risk, and perhaps the one that investors fear most, is loss of principal, total or even partial.

The great recession of 2009 heightened investors’ focus on this area of risk. This anxiety regarding loss has persisted even after two years of healthy gains and recovery for equities in general. Therefore, we offer the following admonition; it would be imprudent to ignore the other faces of risk by excessively focusing only on fear of loss.

The concept of risk is too vast to be covered in one article. Therefore, we will limit our discussion by covering only one additional aspect of risk that we feel is of great importance. Purchasing power risk is one area of concern that we feel has not recently been given the attention it deserves. Money flooding into low yielding treasury bonds provides evidence for this statement.

Investors are so concerned with protecting the nominal value of their principal, that they expose themselves to the ravages of their purchasing power by inflation. More simply stated, it's not enough to merely maintain purchasing power today, it's also imperative to prudently grow purchasing power over time as well. This means increasing both the income and principal components of your portfolios.

Fortunately, the awareness behind the need for both growth of principal and income appears to be building. More and more the investment community is offering articles and discussions about dividend paying common stocks. However, with valuations of many blue-chip dividend paying stalwarts still at historically low valuations, the level of awareness is nascent.

Even though we are encouraged by this growing awareness, we caution that balance must also be maintained. The tug-of-war between investing for growth versus investing for income needs to be properly executed. Otherwise, the investor’s portfolio is at risk of falling into the mud (there's that word risk again).

The pharmaceutical industry appears to offer a fertile field of opportunity for investors seeking growth of principal and growth of income. Valuations look low and therefore, yields are higher than normally expected for this once high-growth sector. But investors need to keep in mind that investing is a dynamic process where the fortunes of individual companies, and even of complete industries, can rapidly change.

Sometimes this occurs as a result of disruptive technologies. Examples would include: Henry Ford and the buggy whip, the Internet and the newspaper industry, and numerous others. Additionally, the fortunes of an industry can face political hurdles (i.e. healthcare reform), and sometimes markets can simply become saturated (i.e. autos and electronics). These are only a few of the reasons why the prospects of an industry or sector can rapidly change. In many ways, the healthcare sector may be facing them all today.

In this article we are going to look at big Pharma through the lens of our F.A.S.T. Graphs research tool. One of the real advantages that our tool offers is the ability to easily review different time frames. We can use it to look at any historical period, for example, 1992 to 2001. One of our favorite exercises when initiating research on a company is to start with a 20 year (our maximum available) historical price and earnings correlated F.A.S.T. Graphs followed by a 15 year, then a 10 year, then a 5 year, etc.

With this exercise we can determine whether growth is accelerating, decelerating or staying the same. We feel this is valuable information to have. For illustration purposes we will offer various F.A.S.T. Graphs over different time frames on our first example Merck & Co. (MRK). Due to space constraints for the remaining companies, we will only provide two historical price and earnings correlated F.A.S.T. Graphs with accompanying performance.

Several beneficial side effects of this analysis will be to provide illumination on the importance of the following three critical investment concepts: 1. Earnings and earnings growth, 2. Dividends and dividend growth, and 3. True Worth valuation-over or under. Our objective is to utilize the research tool to illustrate the effect that each of these metrics have on long-term shareholder returns.

The graphs will show that the rate of change of earnings growth will be the primary determinant of investor returns and the level of dividend income. However, the graphs will further demonstrate how overvaluation will reduce returns and how undervaluation will enhance returns. Consequently, we urge investors to carefully consider each of these three important metrics.

Merck & Co. in the Rearview Mirror

Our first historical price and earnings correlated graphs and accompanying performance results will look at Merck & Co. (MRK) covering the period 1992 to 2001. This was an era where Merck built its reputation as a consistent, above-average growth stock. Merck’s operating excellence and price performance was a poster child for an industry that was considered resilient, if not immune, to economic cycles.

As our population aged, demand for pharmaceuticals was inelastic and compounding at a rapid rate. New product launches with patent protections created numerous blockbuster offerings to profitably feed the insatiable appetite of an aging population.

During this golden age of branded pharmaceuticals, Merck was able to consistently grow earnings in excess of 13% per annum. The stock market liked these consistent results and often richly valued Merck's shares far in excess of their earnings growth rate, except for a brief time in 1993 and 1994. The normal PE ratio (blue line with asterisks) averaged 24.5 but often exceeded this high level. Dividends followed earnings and were increased every year consistent with the growth of earnings.

A couple of interesting takeaways from the graphs on Merck are how a high starting valuation followed by a lower ending valuation over this time frame led to underperformance versus the S&P 500. But most importantly, we draw investors’ attention to the consistent and high earnings growth the company achieved.

Merck: The Golden Age 1992-2001

(Click to enlarge)

Merck: Minimal Growth Migration 2000-2010

Calendar years 2000 through 2010 show a very different Merck than what we saw in the preceding decade. The earnings growth rate not only slowed dramatically only averaging 1.8%, the consistency of their earnings performance also suffered greatly over this time.

Consequently, the stock markets once penchant for richly valuing Merck's shares dissipated and their normal price earnings ratio (blue line with asterisks) was almost cut in half to 13.8. Furthermore, in stark contrast to the previous decade their stock price was below a PE of 13.8 as much or more than it was above it. Its current PE ratio of 11 resides on the low side of historical norms, even during this slow growth era.

Nevertheless, many still think of the Merck of old when considering investing in this blue-chip pharmaceutical giant. The 4.1% current dividend yield and low debt to equity ratio of only 21% appear very attractive. However, we remind the reader that future growth of earnings going forward will determine the future level of dividends.

Note that Merck's dividend has not increased since calendar year 2005. Also, the estimate for 2011 is simply a mathematical calculation and should not be relied upon. Furthermore, also understand that the estimated dividend for calendar year 2011 is not included in the total cash dividends paid column on our graphs.

(Click to enlarge)

With our final historical price and earnings correlated F.A.S.T. Graphs and accompanying performance results on Merck we will shorten our review to cover only the last five years (note that our graphs always include one year of forecasting). Several interesting factors come into play. First, we find that Merck & Co.'s earnings growth rate has averaged 6% per annum since 2006.

Also, we see that valuation has been more reasonable so that principle was at least maintained even though ending valuation is slightly less than beginning was. But perhaps most interestingly, we clearly see the importance of dividends as they represented the bulk of shareholder returns since 2006.


(Click to enlarge)

Analysis: BMY, LLY, PFE, GSK, NVS

On each of the five following major players in big Pharma we will provide historical price and earnings correlated F.A.S.T. Graphs with accompanying performance over two distinct time frames. First we will look at each company over the years 1992 to 2001. The first three examples will include Bristol-Myers Squibb & Co. (BMY), Eli Lilly & Co. (LLY) and Pfizer Inc (PFE). What you'll see is a pattern of consistent above-average earnings growth for each of these companies from 1992 to 2001.

However, our fourth example, GlaxoSmithKline PLC (GSK), will show consistent but lower growth than the first three. Finally, our fifth example Novartis AG (NVS) was created by the merger between Sandoz AG and Ciba-Geigy AG in December 1996.

Our second time frame will cover the more recent historical period 2002 to 2011. As we saw with Merck & Co., four of these five companies will show much lower rates of earnings growth and more cyclicality over this more recent time frame. Novartis AG will be the only exception thanks to their strong generic business (Sandoz-17% of sales) and a more diversified business model. Interestingly, Novartis AG also has the lowest dividend yield of the group and the only one that is below 4%. May we also suggest that you focus on the three critical factors mentioned above as you review each of these historical graphs.

Bristol-Myers: The Golden Age 1992-2001


(Click to enlarge)

Bristol-Myers: Minimal Growth Migration 2002-2011


(Click to enlarge)

Lilly & Co.: The Golden Age 1992-2001


(Click to enlarge)

Lilly & Co.: Minimal Growth Migration 2002-2011


(Click to enlarge)

Pfizer: The Golden Age 1992-2001


(Click to enlarge)

Pfizer: Minimal Growth Migration 2002-2011


(Click to enlarge)

GlaxoSmithKline PLC: The Golden Age 1992-2001


(Click to enlarge)

GlaxoSmithKline PLC: Minimal Growth Migration 2002-2011


(Click to enlarge)

Novartis AG: The Golden Age 1992-2001


(Click to enlarge)

Novartis AG: Minimal Growth Migration 2002-2011


(Click to enlarge)

Conclusions

Some of the best dividend yields available today can be found on big pharma stocks. An equal investment in each of the six examples presented in this article would generate a combined average yield of 4.55%. This is roughly the same yield available today on a 30 year treasury bond.

Furthermore, since each of these companies are currently trading at PE ratios that are historically low relative to this industry's norm and at an approximate 30% to up to 50% discount to the S&P 500, they would, at first glance, appear as enticing purchases. This would be especially true for investors that continue to see this industry as one offering consistent growth and steadily increasing dividends.

However, as the above historical price and earnings correlated F.A.S.T. Graphs illustrate, this industry has experienced major changes over the last decade or so. There are many reasons for this, including the belief by many that new blockbuster drugs based on chemistry are rapidly becoming a thing of the past.

Additionally, even though demographics (mainly an aging world population) should benefit this industry, many political risks to their growth exist. Also the rising cost of healthcare is placing great pressure on this industry's traditional business model. Therefore, current consensus earnings growth forecasts are significantly lower than they were a decade or so ago.

On the other hand, with today's high yields and low valuations even today’s muted growth may offer attractive return potential to include dividend growth. Most of the examples cited above possess good balance sheets and currently generate good cash flows. However, these companies should be evaluated based on their future potential and not their long-standing excellent reputations. The pharmaceutical industry is without a doubt an industry in transition.

Furthermore, we contend that the only logical reason that quality companies like these would trade at a PE ratio lower than the 15 PE that the S&P 500 trades at is if future earnings were expected to collapse. Remember, even a fixed no growth income stream should be worth more than these companies are being capitalized at. Therefore, more than normally, we suggest a comprehensive and thorough research effort prior to investing any money.

Disclosure: I am long NVS.

Disclaimer: The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients. Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted. The information in this document is believed to be accurate, but under no circumstances should a person act upon the information contained within. We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation.


Testimonials


“I appreciate your work, Chuck. As a subscriber to FAST Graphs™, I use the tool to decide on whether to purchase additional shares of what I currently hold or to add a new holding. Your articles help me make full use of the tool and give other readers valuable information, if they take the time to learn. One of the biggest enhancements that I use is the FFO data added for MLPs and REITs.”


“When FAST Graphs™ were unavailable because of Hurricane Sandy, I realized how much I need them in order to make investment decisions.

(Wish I could be) Long FAST Graphs!!!”


“One more vote for the value of FAST Graphs™; just started a subscription to Chuck's great service (premium), and am having a ball analyzing so many stocks quickly.”


“I feel very ill-equipped to make investment decisions without Fast Graphs. :-)”


“Yesterday, I signed up for your F.A.S.T. Graphs™. It's a really amazing, valuable tool for checking over/undervaluation of stocks. Wish I had it years and years ago!!”


“Love the F.A.S.T. Graphs™: One glance and you know a whole lot.”


“About Chuck's F.A.S.T. Graphs™: They are invaluable to me in making decisions about the stocks I own (in addition to what you are saying about doing other research) and the ones I hope to own in the future.”


"Chuck -- Your proprietary F.A.S.T. Graphs™ are a VERY impressive tool!"


“If there were an Investor Hall of Fame for people who have helped others with their investing, and sharing valuable information, you and your F.A.S.T. Graphs™ would get one of my selections.”


“I love Chuck's F.A.S.T. Graphs™! Well worth the price of admission for what he gives you.”


"Chuck - Thank you for your well thought out articles. I tend to be a visual type of person so I really appreciate the F.A.S.T. Graphs™ approach."


"Great article, as always! I always look forward to your articles, and am especially eagerly awaiting your next in this series. I find the F.A.S.T. Graphs™ extremely helpful."


“Your F.A.S.T. Graphs™ put all of this in a single artful picture and the accompanying spreadsheets hammer home the point.”


“I use the F.A.S.T. Graphs™ method to evaluate all of my ideas. I recommend it for individual investors, since it helps them focus on data and get past the many emotional arguments.”


“I recently subscribed to the F.A.S.T. Graphs™, and these articles are helping me learn how to better use them. They really do give you a good quick look at the valuations picture. A much needed tool!”


“I also always appreciate the clear-cut information provided through your F.A.S.T. Graphs™ and articles.”


“Thanks, Chuck, for your F.A.S.T. Graphs™. Each of these graphs is worth 1,000 words in describing a company's growth, consistency and valuation. Thanks for sharing your graphs.”


“Thanks, Chuck. Love the F.A.S.T. Graphs™! It makes investing so much more clear.”


“Chuck's F.A.S.T. Graphs™: They are invaluable to me in making decisions about the stocks I own (in addition to what you are saying about doing other research) and the ones I hope to own in the future.”


”I am amazed at the usefulness of your F.A.S.T. Graphs™ and I plan on using them for a long time to come.”


“Chuck's F.A.S.T. Graphs™ will give you a tool to find those well chosen stocks...”


“Thanks for the F.A.S.T. Graphs™, Chuck. They are the best tool I've used.”


Recent Posts


Tags

GPS TRV GPCM LQDT AVP market timing dividend-paying RRD hyper growth stocks NVS HRS BOKF INTC SHR CIO AMCX due diligence FB UNH investing for total return treasury D OUTR AM X DLR ESI POM FOSL OXY DGAS BR DHR intrinsicvalue EMR, MMM NSC Aristocrat ETP AAN interest rates EMR HCA AEG Champions CGY AGLP SLGN GD CAH UN ULTA MGA PortfolioDesign BRS TEVA ORI BIIB ROST MSCC PBI HOG long-term growth DDS DAN BWLD NROM OGE HCBK WHR PKG COP EE value trap LZB HNZ AFL,CVX,ED,JNJ,MCD,PG,SWK,T,WMT,TGT,ABM,AFL,BEN,BMS,CB,CBSH,CTBI VTR ATHM banks GT XEL Consumer discretionary GOLD DE Utilities Sector PPL UHS AFAM BDX SXL dividends,earnings growth QCOM THFF PII TIS NOG OKE BPL Overvalued economy DividendIncome KO,CLX,CELG,JCP,GT,MSI,PEP,ED TGI FBHS VMI BRLI Telecommunications SBRA DMRC SJM COH ODFL GLT TGT DVA GNTX LINE VFC stock research WAG EXC LLY FOMC CLF CLX,EMR SPLS SWKS AFSI Stock Research Analysis AOS marketvaluation TICC 3NSRGY cyclical WY ACE P dividend-growth ACN ENSG OHI,EPR,WPG,JLL ORCL URI CSCO RSO ConsumerDiscretionary CTCM MAN REITs PCLN regional banks C dividend paying SBR AEP ENDP SCHW FTI,HTZ FLIC DollarCostAverging APEI MAT SNI GOOG DKS EnergySector ACQ CERN JNJ MNK HON DLPH FairlyValued best-of-breed INT TNC ABBV AMAG XOM Valuation ACI AET MATW NSRGY LEN CCK NFLX FairValuation HAS DD suvivorship basis Challengers AMT UTHR FL PEP MO MSFT TSM AIG SHPG GPI WEC WVR BH APH CTL JOY Fundamentals SCG FUL HSNI IR short ideas BNS TUP AIRM stock research tool CACC NOC SPY NLY EK SUBX Industrial ZBRA RMD Dividend Ideas AMG POT UNP earnings utility stocks FLO Macro view BHP market currents AMBN UEPS Market Outlook TMP HCI Share Buybacks MHP RBC GEOS stock analysis CRI BNS. WSM mid-cap fast-growing AFG WFC GPC ABT BMS TNGO FDX BIDU AXP SYY GrowthOriented MPW PFE AKRX ABM VZ DORM diversified machinery CM WFM TE EBAY PRXL NC HGT long ideas CINF food service BMO fastgraphs UL PNM CAT TAC TWGP ITW, ETR intrinsic value,stocks,earnings,fundamentals,stock research tool,due diligence BHB MSA CRLI WU Buffett MHS CXRX ALB VCO DTV PEG DTE OSIS beta PPG TGH true worth FF REXX SIVB HD long-term investing V LH THC ACOM UNM ITW CVX,SWK,MCD,TGT,PG,WMT,JNJ,MDT,AFT,T,ED value-oriented STMP JKHY act AVD GAS ETN fair valuation CanadianBanks CTG dividend income MGEE FAF KCAP INGR ADM SFG stock biotechnology NKE SO MAIN high-yield DividendChampions R CHS stockResearchTool AMZN JCI DELL EAT VRTU investing for income,growth and income CVS GME RJF TEG: WEC: PSX ARRS DR LMT dividend growth investing PNW DRC DIS SAVE SBUX F PCP MCY NEE KMT AGN ONE CHE FinancialSector WASH TEF HPQ TSCO CVX EWBC NA GES QCOR PNR GWW SEIC value investing CTAS WWW SILVER TXT JPM CTBI HCP BBY SCL SAM LOW CPB ROSE DOM ALTE BCR healthcare MMM long-term MNST ARLP BF.B TROW AZO long-term returns growth CMI JWML.Y RY PRAA FAST AMP CB CACI ADT GE LL CASY DTEGY SLW POWR MCK SON BMTC BA Aristocrats RAI JWN SoundValuation MCD MTZ MELI OKS CLX ACM Dividend Champions Bond,TGT,UTX DRI IDA dividend growth market KSS GMCR KFT Contenders SNH CBRL MUR AB PB MDP SYK APD CFR XRX CTSH machinery IBM SHW PNRA RCII blue chip highqualityR DGX AAP MGRC JSFT NTES PM LXU retirement suvivorship AMGN TU ASNA CAPE MKC SYNA PAG BOBE Materials MTW CE RIMM RRC THRM AFL total return WGL CBU macro WMT,ROST,GIS,GE,JNJ,KO blue-chip RTN dividend FC MNR DPS CSX EPHC free cash flow CLR KO CL BAC HCN KALU FISV OHI mid-sized MIDD O ABC ATW EXLS PFG EV biotech UTX dividendpaying DividendAristocrats BBBY RSG BANF InformationTech BCOR HE EMC GILD PRGO BCE HRL SNCR BigFive,Canadian ECHO NSR earnings growth NPM CBI ED:SCG fundamental stock research tool DFS HBI CHD cash flow US Economy BKH IPAR capital appreciation DOV BLL ED FTR fair value portfolio ECL CNSL WLP SHOO FAST Graphs LKQ FRED INWK COL BLK ACR dividend paying stocks value SIG PG HII LLL DECK WIN WRLD HIBB TOT sell CNC growth stocks KMP CELG ZUMZ RSG,RTN POR dividendGrowth WST DNB ADP RKT long DOW MYL HSY MRK KR CKSW BG CTRX INFY BAX LO AZZ dividends T consumer THO IR, RS WMT COO BAP JCOM GOOGL STE LTM HighQuality cashflow Yield COST BEAV CPN GIS K TWX WBA IBN FDO intrinsic value PDFS ICLR BOFI investing for income CAM JAZZ ITC InterestRates AAPL SWFT FCFS SWK FRAN ESRX JRN MA BWP BEN DRIP ANDE Utilities SRCE HP M CR technology CATY investment OII KMB VAL MCHP stocks TIF BMRC CSL OZRK RDS.A VRX HSC SU SYT ANTM MNTX VVC PCL AA MDT investing

Archive

Testimonials


“I appreciate your work, Chuck. As a subscriber to FAST Graphs™, I use the tool to decide on whether to purchase additional shares of what I currently hold or to add a new holding. Your articles help me make full use of the tool and give other readers valuable information, if they take the time to learn. One of the biggest enhancements that I use is the FFO data added for MLPs and REITs.”


“When FAST Graphs™ were unavailable because of Hurricane Sandy, I realized how much I need them in order to make investment decisions.

(Wish I could be) Long FAST Graphs!!!”


“One more vote for the value of FAST Graphs™; just started a subscription to Chuck's great service (premium), and am having a ball analyzing so many stocks quickly.”


“I feel very ill-equipped to make investment decisions without Fast Graphs. :-)”


“Yesterday, I signed up for your F.A.S.T. Graphs™. It's a really amazing, valuable tool for checking over/undervaluation of stocks. Wish I had it years and years ago!!”


“Love the F.A.S.T. Graphs™: One glance and you know a whole lot.”


“About Chuck's F.A.S.T. Graphs™: They are invaluable to me in making decisions about the stocks I own (in addition to what you are saying about doing other research) and the ones I hope to own in the future.”


"Chuck -- Your proprietary F.A.S.T. Graphs™ are a VERY impressive tool!"


“If there were an Investor Hall of Fame for people who have helped others with their investing, and sharing valuable information, you and your F.A.S.T. Graphs™ would get one of my selections.”


“I love Chuck's F.A.S.T. Graphs™! Well worth the price of admission for what he gives you.”


"Chuck - Thank you for your well thought out articles. I tend to be a visual type of person so I really appreciate the F.A.S.T. Graphs™ approach."


"Great article, as always! I always look forward to your articles, and am especially eagerly awaiting your next in this series. I find the F.A.S.T. Graphs™ extremely helpful."


“Your F.A.S.T. Graphs™ put all of this in a single artful picture and the accompanying spreadsheets hammer home the point.”


“I use the F.A.S.T. Graphs™ method to evaluate all of my ideas. I recommend it for individual investors, since it helps them focus on data and get past the many emotional arguments.”


“I recently subscribed to the F.A.S.T. Graphs™, and these articles are helping me learn how to better use them. They really do give you a good quick look at the valuations picture. A much needed tool!”


“I also always appreciate the clear-cut information provided through your F.A.S.T. Graphs™ and articles.”


“Thanks, Chuck, for your F.A.S.T. Graphs™. Each of these graphs is worth 1,000 words in describing a company's growth, consistency and valuation. Thanks for sharing your graphs.”


“Thanks, Chuck. Love the F.A.S.T. Graphs™! It makes investing so much more clear.”


“Chuck's F.A.S.T. Graphs™: They are invaluable to me in making decisions about the stocks I own (in addition to what you are saying about doing other research) and the ones I hope to own in the future.”


”I am amazed at the usefulness of your F.A.S.T. Graphs™ and I plan on using them for a long time to come.”


“Chuck's F.A.S.T. Graphs™ will give you a tool to find those well chosen stocks...”


“Thanks for the F.A.S.T. Graphs™, Chuck. They are the best tool I've used.”